Alzheimer's vaccine takes first step in human trial

NCT ID NCT06831812

Completed Prevention Sponsor: Nuravax, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a vaccine called AV-1959R, designed to prevent Alzheimer's disease by targeting a protein linked to the condition. Sixteen healthy adults aged 40-60 will receive three shots of the vaccine or a placebo over 14 weeks. Researchers will monitor for side effects and measure immune responses to see if the vaccine is safe and triggers the desired effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AV-1959R (beta-amyloid vaccine)
What this could lead to: If successful, this could lead to a vaccine that prevents Alzheimer's disease by training the immune system to clear harmful brain proteins.
What could go wrong: This is an early Phase 1 trial with only 16 healthy participants, so safety and immune response are unproven. The vaccine may not work in larger studies or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE ALZHEIMER DISEASE (AD) ALZHEIMERS DISEASE PREVENTION

Contacts and locations

Show contact details

Locations

Arvax

Adelaide, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.